Edgar Filing: Danos Olivier - Form 4

Danos Olivier Form 4											
January 07, 20								OM	1B Af	PROVAL	L
FORM	UNITED	STATES		RITIES A			COMMISSIO	N OMB Numbe	ər:	3235-0)287
Check this box if no longer subject to Section 16. Form 4 or						F Estima burder respon	Expires:January 31, 2005Estimated average burden hours per response0.5				
obligations may continu <i>See</i> Instruct 1(b).	section 17(a) of the l	Public U	Itility Hol	ding Con		nge Act of 1934 of 1935 or Sect 940				
(Print or Type Res	sponses)										
1. Name and Address of Reporting Person <u>*</u> Danos Olivier			2. Issuer Name and Ticker or Trading Symbol REGENXBIO Inc. [RGNX]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				Date of Earliest Transaction							
	KBIO INC., 96 L ROAD, SUI		(Month/) 01/03/2	Day/Year) 2019			Director Officer (gi below) Chie	ve title below ef Scientific	_Othe v)	o Owner er (specify er	
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
ROCKVILLE	, MD 20850						Person	More than C	ne Re	porting	
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securities A	cquired, Disposed	of, or Bene	ficial	ly Owned	
	Transaction Date Ionth/Day/Year)	2A. Deema Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8) Code V	4. Securit mAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownersh Form: Dire (D) or Indi (I) (Instr. 4)	ect rect	7. Nature (Indirect Beneficial Ownership (Instr. 4)	l
	<i>.</i>	C 1 1	C			(D) Price	· 1· 4				
Reminder: Report	t on a separate line	or each cl	ass of sec	urities bene	Perso inform requir	ns who res nation cont ed to resp ys a curre	or indirectly. spond to the collection tained in this forr ond unless the for ntly valid OMB co	n are not orm	S	EC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	J
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	

8 E S

Edgar Filing: Danos Olivier - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Y	Year) (Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				(
			Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 40.82	01/03/2019	А	48,000	<u>(1)</u>	01/03/2029	Common Stock	48,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
Danos Olivier C/O REGENXBIO INC. 9600 BLACKWELL ROAD, SUITE 210 ROCKVILLE, MD 20850			Chief Scientific Officer				
Signatures							
/s/ Patrick J. Christmas as attorney-in-fact	01/07/201	9					
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(